Astellas Pharma Inc (ALPMF PINK) stock market data APIs
$12.6325
0(0%)
as of November 21, 2025
Try our APIs with
free plan!
Astellas Pharma Inc Financial Data Overview
Price chart is built with
Anychart
Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company offers XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for acute myeloid leukemia (AML); VYLOY, a treatment for gastric cancer; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also provides VEOZAH, a treatment for vasomotor symptoms due to menopause; IZERVAY, a treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD); EVRENZO, a treatment for anemia associated with chronic kidney disease (CKD); Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf, an immunosuppressants. It has a research collaboration with xFOREST Therapeutics to develop RNA-targeted therapies and a partnership agreement with Roche Diabetes Care Japan Co., Ltd. to develop and commercialize integrated diabetes self-management solution. It offer its products to oncology, ophthalmology, urology, immunology, and women's health areas. The company was formerly known as Yamanouchi Pharmaceutical Co. Ltd. and changed its name to Astellas Pharma Inc. in April 2005. Astellas Pharma Inc. was founded in 1923 and is headquartered in Chuo, Japan.
Prev. Close
12.6325
Open
12.6325
High
12.6325
Low
12.6325
52 wk Range
8.405-12.72
Market Cap
22 461 M
P/E Ratio
27.7273
Shares Outstanding
1 791 M
Revenue
2 006 816 M
EPS
0.2988
Dividends (Yield)
0.0428
Beta
0.072
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Astellas Pharma Inc data using free add-ons & libraries
Get Astellas Pharma Inc Fundamental Data
Astellas Pharma Inc Fundamental data includes:
- Net Revenue: 2 006 816 M
- EBITDA: 563 083 M
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-10-30
- EPS/Forecast: 15.97
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Astellas Pharma Inc News
New
Sector Update: Health Care Stocks Higher Late Afternoon
Health care stocks were higher late Friday afternoon, with the NYSE Health Care Index and the Health PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscri...
U.S. FDA Approves PADCEV® plus Keytruda® for Certain Patients with Bladder Cancer
PADCEV plus Keytruda is the first and only approved perioperative treatment regimen that can significantly improve survival over current standard of care (surgery alone) in cisplatin-ineligible patien...
Merck Keytruda formulations approved in U.S. for bladder cancer
[Headquarters of US Food and Drug Administration (FDA)] Grandbrothers/iStock Editorial via Getty Images The U.S. Food and Drug Administration (FDA) on Friday approved injectable and intravenous versi...
Can Linzess Continue to Aid IRWD's Top Line After a Strong Q3?
Ironwood Pharmaceuticals’ IRWD sole marketed product, Linzess (linaclotide), has witnessed a strong uptake in recent quarters. The company markets Linzess in the United States in collaboration with ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
